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Abstract 
Background: A malaria hotspot in the southeastern region of Mauritania, near the Malian border, may hamper 
malaria control strategies. The objectives were to estimate the prevalence of genetic polymorphisms associated with 
drug resistance in Plasmodium falciparum isolates and establish baseline data.
Methods: The study was conducted in two malaria-endemic areas in Hodh Elgharbi, situated in the Malian–Maurita-
nian border area. Blood samples were collected from symptomatic patients. Single nucleotide polymorphisms in Pfcrt, 
Pfmdr1, Pfdhfr, and Pfdhps were genotyped using PCR-restriction fragment length polymorphism, DNA sequencing 
and primer extension. The Pfmdr1 gene copy number was determined by real-time PCR.
Results: Of 280 P. falciparum-infected patients, 193 (68.9%) carried the Pfcrt 76T mutant allele. The Pfmdr1 86Y and 
184F mutations were found in 61 (23.1%) of 264 isolates and 167 (67.6%) of 247 samples that were successfully geno-
typed, respectively. Pfmdr1 mutant alleles 1034C, 1042D and 1246Y were rarely observed. Of 102 P. falciparum isolates 
analysed, ten (9.8%) had more than one copy of Pfmdr1 gene. The prevalence of isolates harbouring at least triple 
mutant Pfdhfr 51I, 59R, 108 N/T was 42% (112/268), of which 42 (37.5%) had an additional Pfdhps 437G mutation. The 
Pfdhps 540E mutation was observed in four isolates (1.5%), including three associated with Pfdhfr triple mutant. Only 
two quintuple mutants (Pfdhfr-51I-59R-108N Pfdhps-437G-540E) were observed.
Conclusions: The observed mutations in Pfdhfr, Pfdhps, Pfmdr1, and Pfcrt may jeopardize the future of seasonal 
malaria chemoprevention based on amodiaquine-sulfadoxine-pyrimethamine, intermittent preventive treatment for 
pregnant women using sulfadoxine-pyrimethamine, and treatment with artesunate-amodiaquine. Complementary 
studies should be carried out to document the distribution, origin and circulation of P. falciparum populations in this 
region and more widely in the country to assess the risk of the spread of resistance.
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Background
Before 2006, chloroquine and sulfadoxine-pyrimeth-
amine were the first- and second-line drugs in Mauri-
tania, respectively. The current anti-malarial treatment 
policy in Mauritania is based on artesunate-amodiaquine 
and artemether-lumefantrine as the first- and second-line 
treatment of uncomplicated malaria, respectively, regard-
less of Plasmodium spp. [1]. The efficacy and tolerance 
of artesunate-amodiaquine treatment have been con-
firmed in a recent clinical study conducted in southern 
Mauritania [2]. The Mauritanian Ministry of Health also 
recommends the use of sulfadoxine-pyrimethamine (SP) 
for intermittent preventive treatment to prevent malaria 
during pregnancy, particularly during the first and sec-
ond pregnancies [3]. Due to the scarcity of clinical data 
on anti-malarial drug efficacy in Mauritania, molecular 
markers of drug resistance are convenient surrogate indi-
cators to monitor and detect emergence of drug-resistant 
Plasmodium falciparum.
Dihydrofolate reductase (DHFR) and dihydropteroate 
synthase (DHPS) are known targets of pyrimethamine 
and sulfadoxine, respectively [4]. These drugs specifi-
cally inhibit the enzymes of the folate pathway to kill the 
parasites. P. falciparum chloroquine resistance trans-
porter (Pfcrt) and P. falciparum multidrug resistance 
gene 1 (Pfmdr1) encode membrane transporters that 
have been associated with resistance to chloroquine and 
amodiaquine (Pfcrt) or chloroquine, amodiaquine, and 
amino-alcohols (mefloquine, lumefantrine; Pfmdr1). The 
mode of action of chloroquine and other quinoline-like 
drugs involves an interference with the plasmodial haem 
metabolism in the digestive vacuole. Chloroquine-resist-
ant P. falciparum parasites either diminish the influx of 
chloroquine into the food vacuole or enhance efflux of 
chloroquine from the food vacuole, or both, resulting in a 
decreased drug accumulation within the food vacuole [5]. 
Distinct point mutations in Pfdhfr, Pfdhps and Pfcrt con-
fer resistance to pyrimethamine, sulfadoxine and chlo-
roquine/amodiaquine, respectively. Some studies have 
suggested that point mutations in Pfmdr1 are associated 
with resistance to quinoline-like drugs and artemisinin 
derivatives, but their role is not yet well established [6, 
7]. Moreover, it has been reported that treatment with 
artemether-lumefantrine selects for the pfmdr1 wild-type 
N86 allele [8–10]. Pfmdr1 amplification resulting in mul-
tiple gene copies is associated with resistance to amino 
alcohols (mefloquine and lumefantrine) [4, 11]. Recent 
studies have demonstrated that mutations in Kelch pro-
peller 13 is directly associated with artemisinin resistance 
[12].
Hodh Elgharbi region is one of the eight Mauritanian 
administrative regions where malaria transmission is sea-
sonal, with the peak occurring in September and October. 
Several studies have shown that P. falciparum is the pre-
dominant malaria species in this region and that 30–83% 
of febrile patients are infected with malaria parasites dur-
ing the transmission season [2, 13–16]. In Hodh Elgharbi 
region, the northern Saharo–Sahelian area that borders 
the Saharan desert has been considered as malaria-free 
while the southern Sahelian part of the region is classified 
as holo-endemic [13]. The Malian–Mauritanian border is 
particularly vulnerable to the spread of malaria parasites 
with the influx of war refugees from the Malian side of 
the frontier. The problem of human population move-
ment is further compounded by the presence of popula-
tions leading a nomadic lifestyle in this agropastoral area. 
The situation in Mali near the border area is quite similar 
in terms of malaria epidemiology and chloroquine resist-
ance [17, 18].
The objective of the present study was to compare the 
prevalence of Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps muta-
tions and the copy number of Pfmdr1 gene in P. falcipa-
rum isolates collected in two areas with different malaria 
endemicity in Hodh Elgharbi region after the introduc-
tion of artemisinin-based combination therapy (ACT) in 
2006, in order to establish a baseline database for moni-
toring drug-resistant P. falciparum in the malaria hotspot 
in the Malian–Mauritanian border area.
Methods
Study area
The study was conducted in Hodh Elgharbi, which covers 
a surface area of 53,400 sq km and is composed of four 
districts (Aioun (the provincial capital), Kobeni, Tam-
chekett, Tintane). Kobeni city is located about 18  km 
from the Malian–Mauritanian border. Aioun and Tintane 
are located approximately 103 and 174 km to the north 
and northwest of Kobeni city, respectively. The popula-
tion of Hodh Elgharbi is approximately 294,109 inhabit-
ants [19]. The location and Saharo–Sahelian (Aioun and 
Tintane) and Sahelian (Kobeni) climates were described 
in an earlier study [16]. Human activities are dominated 
by livestock rearing (mainly cattle, sheep, and goats) and 
agriculture (mainly millet). There are five public health 
centres in Hodh Elgharbi, one health centre in each of its 
four districts and one hospital in Aioun.
Patients and blood sample collection
Between September and October 2010, corresponding 
to the peak season of malaria transmission, all febrile 
patients were enrolled after informed written consent. A 
rapid diagnostic test for malaria (SD Bioline P. falciparum 
histidine-rich protein II and Plasmodium vivax plasmo-
dial lactate dehydrogenase antigen rapid diagnostic test; 
Standard Diagnostics, Inc, Yongin, Republic of Korea) 
was performed, and Giemsa-stained thin and thick blood 
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films were prepared and examined under the microscope. 
Fifty µl of blood sample were spotted directly on What-
man 3MM filter paper, dried, and stored at room temper-
ature for molecular analysis.
Genetic characterization of Plasmodium falciparum isolates
Total genomic DNA of each isolate, including human 
DNA, was extracted using the MaxMag™DNA Multi-
Sample kit (Applied Biosystems, Warrington, UK) fol-
lowing the manufacturer’s instructions. All molecular 
experiments were performed at the parasitology labora-
tory in Marseille, France in 2012–2013.
Pfcrt single‑nucleotide polymorphisms
Codon 76 (K76T, PlasmoDB single nucleotide polymor-
phism (SNP) ID: Pf3D7_07_v3: 403,625) was genotyped 
by restriction fragment length polymorphism (RFLP) 
as detailed elsewhere [20]. Pfcrt (PF3D7_0709000) was 
amplified by semi-nested PCR with fluorescent end-
labelled primers  (Table  1). First and second rounds of 
PCR had the same cycling conditions: 94 °C for 2 min, 10 
cycles of 94 °C × 20 s, 50 °C × 20 s and 60 °C × 30 s, 35 
cycles of 94 °C × 20 s, 45 °C × 20 s and 60 °C × 30 s, and 
a final 5-min extension step at 60 °C. The 6-FAM-labelled 
product (1 µl) was digested with 1.2 units of ApoI (New 
England Biolabs, Evry, France) at 50 °C for 3 h in a 30 µl 
reaction. Labelled and restricted products were diluted 
100×  and detected on ABI 3130XL capillary sequencer 
(Applied Biosystems) using Genescan 120  LIZ® size 
standards. Genomic DNA from P. falciparum reference 
clones 3D7/unknown origin (wild-type) and W2/Indo-
china (mutant) was used as positive controls, and water 
and human DNA were used as negative controls.
Pfmdr1 SNPs
Pfmdr1 (PF3D7_0523000) genotyping was performed by 
Sanger’s method of DNA sequencing. Four pairs of prim-
ers were used to amplify two Pfmdr1 fragments carrying 
five polymorphisms associated with drug resistant phe-
notype (Table 1). N86Y and Y184F were on the first frag-
ment MDR1-1 (590 base pairs, bp) and S1034C, N1042D 
and D1246Y on fragment MDR1-2 (968  bp). The reac-
tion mixture, PCR conditions, amplicons purification and 
sequencing were described in previous studies [20, 21].
Pfdhps and Pfdhfr SNPs
Pfdhps and Pfdhfr genes were amplified by nested PCR 
and genotyped using a rapid primer extension method 
 (Snapshot®), as previously described [22]. The follow-
ing SNPs were determined: Pfdhps (PF3D7_0810800) 
S436F/A, A437G, K540E, A581G and A613S and Pfd-
hfr (PF3D7_0417200) A16V, N51I, C59R, S108 N/T, and 
I164L. Primer extension was performed and analysed by 
capillary electrophoresis on polyacrylamide gels using 
ABI 3130XL sequencer (Applied Biosystems). Electro-
phoregram was interpreted using  Genemapper® 4.0 soft-
ware (Applied Biosystems, Carlsbad, CA, USA).
Pfmdr1 gene copy number
Pfmdr1 copy number was determined using TaqMan 
real-time PCR (7900HT Fast Real-Time PCR system, 
Applied Biosystems, Courtaboeuf, France) using the 
single-copy gene β-tubulin (PF10_0084) as the reference. 
Each sample selected on the basis of a sufficient amount 
of DNA was genotyped in duplicate. The sequence of 
oligonucleotide primers and probes used, the prepara-
tion of reaction mixture, PCR conditions, and evaluation 
of PCR efficiency were described in detail in a previous 
study [21]. DNA extracted from the P. falciparum 3D7 
reference clone, which has a single copy of each gene, 
was used as a calibrator, and β-tubulin housekeep-
ing gene was used as a control in all experiments. The 
number of gene copy was determined using the  2−ΔΔCt 
method [11].
Statistical analysis
Based on similar epidemiological and ecological char-
acteristics in the study sites of Aioun and Tintane [16], 
data from these two districts were pooled and com-
pared to those from Kobeni. The frequency of a par-
ticular mutant allele was calculated as the proportion of 
the specific mutant samples among the total number of 
samples successfully analysed for this mutation. Similarly, 
the frequencies of double, triple, quadruple, and quintu-
ple mutants were determined as the proportion of sub-
jects with two, three, four, or five mutations among the 
total numbers of samples tested. Pairwise comparison 
of mutation frequencies between the northern (Aioun 
and Tintane) and southern (Kobeni) sites was performed 
using the Chi square test. The distribution of Pfmdr1 and 
Pfcrt SNPs in relation to Pfmdr1 copy number was com-
pared using Fisher’s exact test. For statistical analyses, 
mixed alleles were considered to be mutant. The P value 
of ≤0.05 was considered as statistically significant.
Results
The clinical characteristics of the patients and parasito-
logical features were published elsewhere [16]. In that 
study, laboratory diagnosis was based on microscopy and 
rapid diagnostic test. Plasmodium falciparum mono-
infection was confirmed by PCR in 299 (146 in Kobeni, 
92 in Tintane, and 61 in Aioun) patients. Plasmodium 
vivax was detected by PCR in 11 additional patients (nine 
in Kobeni, two in Tintane, none in Aioun).
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Pfcrt polymorphisms
The key codon 76 was examined in the Pfcrt gene 
(Table 2). The mutant allele 76T was identified in 193 of 
280 (68.9%) samples that were successfully amplified, of 
which 160 (57.1%) were pure mutant allele and 33 (11.8%) 
had mixed alleles with both K76 and 76T. The difference 
in the proportions of mutant and mixed alleles in Kob-
eni and Tintane/Aioun was not statistically significant 
(P > 0.05).
Pfdhps and Pfdhfr polymorphisms
The results of Pfdhps and Pfdhfr polymorphisms are sum-
marized in Tables  3, 4 and 5. Of 299 available samples, 
Pfdhps PCR genotyping was successful in 264 (88.3%) 
samples for codons 436, 540, 581, and 613 (263 samples 
for codon 437). The most prevalent Pfdhps mutations 
affected the codons 436 (S436A) and 437 (A437G), which 
were present as pure mutants in 144 of 264 (55%) and 60 
of 263 (23%) samples, respectively (Table 3). In these two 
codons, mixed alleles were observed in 36 of 264 (14%) 
and 31 of 263 (12%) samples, respectively. At the district 
level, samples from Kobeni exhibited the highest preva-
lence for S436A mutation (72.2%; n  =  75 pure mutant 
allele and 16 mixed alleles) compared to Tintane and 
Aioun (64.5%; n =  69 pure mutant allele and 20 mixed 
alleles) districts, but the difference between these two 
areas in Hodh Elgharbi was not statistically significant 
(P > 0.05). The presence of A437G substitution is one of 
the hallmarks of sulfadoxine resistance. The proportion 
of isolates with pure or mixed A437G alleles was higher 
in Tintane and Aioun (61 of 137; 44%) than in Kobeni 
(30 of 126; 24%) (P  <  0.05). However, K540E substitu-
tion, which together with A437G change is associated 
with sulfadoxine resistance, was rarely observed (2%) 
among the isolates collected in Hodh Elgharbi region. 
All isolates carried wild-type alleles in codons 581 and 
613. Pure AAKAA haplotype was the most commonly 
observed Pfdhps haplotype (127 of 264, 48%), followed by 
SGKAA, which occurred in 71 (38 pure and 33 mixed) of 
264 (26.9%) samples (Table 4). 
Table 1 Pfdhfr, Pfdhps, Pfmdr1 and Pfcrt PCR primer sequences used in amplification reactions
Gene Protocol step Primers Primers sequences
Pfdhfr PCR I F 5′-TTC TCC TTT TTA TGA TGG AAC AAG T-3′
R 5′ ATA TTT GAA AAT CAT TTG GAT GTA TAG-3′
PCR II F 5′-GTT GAA CCT AAA CGT GCT GT-3′
R 5′-TTC ATC ATG TAA TTT TTG TTG TG-3′
Multiplex Pfdhfr51F 5′-AGG AGT ATT ACC ATG GAA ATG TA-3′
Pfdhfr16R 5′-GAC TGA CTC TCA TTT TTG CTT TCA ACC TTA CAA CAT-3′
Pfdhfr108F 5′-GAC TGA CTA CAA AAT GTT GTA GTT ATG GGA AGA ACA A-3′
Pfdhfr164R 5′-CTG ACT GAC TGA CTG ACT AAT TCT TGA TAA ACA ACG GAA CCT CCT A-3′
Pfdhfr59R 5′-CTG ACT GAC TGA CTG ACT GAC TTG ATT CAT TCA CAT ATG TTG TAA CTG CAC-3′
Pfdhps PCR I F 5′-TGC TTA AAT GAT ATG ATA CCC GAA TAT AAG-3′
R 5′ TCC ACC TGA AAA GAA ATA CAT AAA T-3′
PCR II F 5′-GTT GAA CCT AAA CGT GCT GT-3′
R 5′-TTC ATC ATG TAA TTT TTG TTG TG-3′
Multiplex Pfdhps613R 5′-TTG ATC ATT CAT GCA ATG GG-3′
Pfdhps540F 5′-GAC TGA GGA AAT CCA CAT ACA ATG GAT-3′
Pfdhps581R 5′-TAA GAG TTT AAT AGA TTG ATC ATG TTT CTT C-3′
Pfdh436-1F 5′-GAC TGA CTA GTG TTA TAG ATA TAG GTG GAG AAT CC-3′
Pfdhps436-2R 5′-GAC TGA CTG ACT GAC TTG GAT TAG GTA TAA CAA AAA GGA ICA-3′
Pfdhps437R 5′-GAC TGA CTG ACT GAC TGA CTT TTT TGG ATT AGG TAT AAC AAA AGG A-3′
Pfmdr1 PfMDR1- 1 F 5′-AGA GAA AAA AGA TGG TAA CCT CAG-3′
R 5′-ACC ACA AAC ATA AAT TAA CGG-3′
PfMDR1- 2 F 5′-CAG GAA GCA TTT TAT AAT ATG CAT-3′
R 5′-CGT TTA ACA TCT TCC AAT GTT GCA-3′
Pfcrt PCR I F 5′-GTT CTT GTC TTG GTA AAT GT-3′
R 5′- CGG ATG TTA CAA AAC TAT AGT T-3′
PCR II F 5′-GTT CTT GTC TTG GTA AAT GT-3′
R 6-FAM-5′- TAA ATG TGC TCA TGT GTT TA -3′
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Table 2 Prevalence of Pfmdr1 and Pfcrt point mutations in  isolates from three health facilities in Hodh Elgharbi region 
in Mauritania
aa amino acid, n number of isolates
Gene Codons Aa n (%)
Aioun Kobeni Tintane Total
Pfcrt K76T K 12 (21) 42 (31) 33 (38) 87 (31)
K/T 8 (14) 15 (11) 10 (11) 33 (12)
T 36 (64) 80 (58) 44 (51) 160 (57)
Pfmdr1 N86Y N 35 (70) 102 (77) 66 (80) 203 (77)
Y 15 (30) 30 (23) 16 (20) 61 (23)
Y184F Y 14 (33) 46 (36) 20 (26) 80 (32)
F 29 (67) 81 (64) 57 (74) 167 (68)
S1034C S 29 (100) 67 (96) 53 (98) 149 (97)
C 0 3 (4) 1 (2) 4 (3)
N1042D N 29 (100) 76 (99) 49 (100) 154 (99)
D 0 1 (1) 0 1 (1)
D1246Y D 37 (100) 81 (98) 70 (100) 188 (99)
Y 0 2 (2) 0 2 (1)
Table 3 Prevalence of Pfdhps and Pfdhfr mutations in isolates collected in three health facilities in Hodh Elgharbi region, 
Mauritania in 2010
aa amino acid, n number of isolates. All isolates had the wild-type Pfdhps alleles in codons 581 and 613. Mutant alleles are denoted in bold characters
Gene Codon Aa n (%)
Aioun Kobeni Tintane Total
Pfdhps S436A/F S 17 (32) 33 (26) 32 (38) 82 (31)
S/A 10 (19) 16 (13) 10 (12) 36 (14)
A 26 (49) 75 (60) 43 (51) 144 (55)
F 0 2 (2) 0 2 (1)
A437G A 33 (62) 96 (76) 43 (51) 172 (65)
A/G 10 (19) 12 (10) 9 (11) 31 (12)
G 10 (19) 18 (14) 32 (38) 60 (23)
K540E/A K 52 (98) 122 (97) 85 (100) 259 (98)
K/A 0 1 (0.8) 0 1 (0.4)
K/E 0 2 (2) 0 2 (1)
E 1 (2) 1 (1) 0 2 (1)
Pfdhfr N51I N 31 (58) 73 (55) 39 (47) 143 (53)
N/I 10 (19) 16 (12) 11 (13) 37 (14)
I 12 (23) 44 (33) 33 (40) 89 (33)
C59R C 32 (60) 68 (51) 40 (48) 140 (52)
C/R 9 (17) 18 (14) 9 (11) 36 (13)
R 12 (23) 47 (35) 34 (41) 93 (35)
S108N/T S 31 (58) 68 (52) 42 (51) 141 (53)
S/T 1 (2) 3 (2) 1 (1) 5 (2)
S/N 7 (13) 14 (11) 6 (7) 27 (10)
T/N 2 (4) 1 (1) 6 (7) 9 (3)
T 2 (4) 0 1 (1) 3 (1)
N 10 (19) 46 (35) 27 (33) 83 (31)
I164L I 52 (98) 131 (99) 73 (88) 256 (96)
I/L 1 (2) 1 (1) 10 (12) 12 (4)
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Of 299 samples, Pfdhfr PCR genotyping was success-
ful in 269 (90.0%; codons 51 and 59) and 268 (89.6%; 
codons 108 and 164), respectively. The results for Pfdhfr 
polymorphisms showed that at four (51, 59, 108, 164) 
explored codons, pure mutant or mixed alleles were 
present in 126 of 269 (46.8%), 129 of 269 (48.0%), 127 of 
268 (47.4%), and 12 of 268 (4.5%), respectively (Table 3). 
The proportions of mutant N51I, C59R and S108  N/T 
alleles did not differ significantly between Kobeni and 
Tintane-Aioun (P > 0.05). All isolates with mutant 164L 
had mixed alleles, and there were more isolates with 
mixed 164 alleles in Tintane and Aioun than in Kobeni 
(P  <  0.05). The pure wild-type Pfdhfr ANCSI haplotype 
was identified in 64 of 133 (48.1%) and 63 of 136 (46.3%) 
samples in Kobeni and Tintane-Aioun (P > 0.05), respec-
tively, with a global prevalence of 47.2% (127 of 269) 
(Table  5). A single mutant (ANCNI) was not observed. 
Pure double mutants (AICNI or ANRNI) occurred rarely 
(seven of 269, 2.6%). The triple pure mutant haplotype, 
AIRNI, was detected in 41 of 133 (30.8%) and 31 of 136 
(22.8%) malaria-positive samples in Kobeni and Tintane-
Aioun districts (P  >  0.05), respectively, with an overall 
prevalence of 27% (72 of 269).
There were three isolates with quadruple mutations 
(i.e., triple Pfdhfr mutant haplotype AIRNI and single 
Pfdhps mutant haplotype SGKAA). Quintuple mutation, 
i.e., SGEAA haplotype associated with the triple Pfdhfr 
mutant haplotype AIRNI, was observed in two isolates.
Pfmdr1 polymorphisms
A total of 264, 247, 153, 155, and 190 samples were suc-
cessfully genotyped for Pfmdr1 codons 86, 184, 1034, 
1042, and 1246, respectively (Table 2). In all investigated 
codons, wild-type alleles predominated, except for codon 
184 in which the mutant allele 184F occurred more fre-
quently (68%; 167 of 247), compared to the wild-type 
allele Y184. Mixed pfmdr1 alleles were not observed. The 
proportions of mutant alleles at each codon did not dif-
fer significantly (P  >  0.05) between the northern (Tin-
tane and Aioun) and southern (Kobeni) districts of Hodh 
Elgharbi region.
Pfmdr1 copy number
Due to insufficient DNA left after characterizing four 
molecular markers, the copy number of Pfmdr1 was 
determined in 102 isolates (88 isolates from Kobeni and 
14 from Tintane and Aioun) (Table  6). All 102 isolates 
were successfully genotyped. Only one isolate (one of 
102, 1.0%) was characterized with three copies of Pfmdr1. 
Table 4 Prevalence of  wild-type and  mutant Pfdhps hap-
lotypes in  isolates collected from  three health facilities 
in Hodh Elgharbi region in Mauritania in 2010
a Wild-type haplotype. The haplotypes of one isolate from Tintane (SN/AKAA, 
N = undetermined amino acid) and one isolate from Kobeni (SGEAN/A) were 
not fully characterized
Haplotypes n (%)
Aioun Kobeni Tintane Total
SAKAAa 10 (19) 18 (14) 6 (7) 34 (13)
AA/GKAA 2 (4) 2 (2) 3 (4) 7 (3)
AAKAA 22 (42) 69 (55) 36 (42) 127 (48)
AGKAA 2 (4) 4 (3) 4 (5) 10 (4)
FAKAA 0 2 (2) 0 2 (1)
S/AA/GKAA 6 (11) 9 (7) 4 (5) 19 (7)
S/AAK/EAA 0 1 (1) 0 1 (0.4)
S/AAKAA 1 (2) 6 (5) 1 (1) 8 (3)
SA/GKAA 2 (4) 1 (1) 2 (2) 5 (2)
SGEAA 1 (2) 0 0 1 (0.4)
SGK/AAA 0 1 (1) 0 1 (0.4)
SGK/EAA 0 1 (1) 0 1 (0.4)
SGKAA 4 (8) 11 (9) 23 (27) 38 (14)
Total 53 (100) 126 (100) 85 (100) 264 (100)
Table 5 Prevalence of Pfdhfr mutant haplotypes in isolates 
from three health facilities in Hodh Elgharbi, Mauritania
a Pure wild-type Pfdhfr haplotype. The complete haplotype of one isolate was 
not determined (AIRNN, N not determined)
Haplotype n (%)
Aioun Kobeni Tintane Total
ANCSIa 28 (53) 64 (48) 35 (42) 127 (47)
ANCS/TI 1 (2) 2 (2) 0 3 (1)
ANC/RSI 0 1 (1) 0 1 (0.4)
ANC/RS/NI 0 3 (2) 1 (1) 4 (1)
ANCSI/L 1 (2) 0 2 (2) 3 (1)
AN/IC/RS/NI 6 (11) 11 (8) 4 (5) 21 (8)
AN/IC/RS/NI/L 0 0 1 (1) 1 (0.4)
AN/IC/RS/TI 0 1 (1) 0 1 (0.4)
AN/IC/RSI 1 (2) 2 (2) 2 (2) 5 (2)
AN/IC/RSI/L 0 0 1 (1) 1 (0.4)
AN/ICS/TI/L 0 0 1 (1) 1 (0.4)
AN/ICSI 1 (2) 1 (1) 0 2 (1)
AN/ICSI/L 0 0 2 (2) 2 (1)
AN/IRNI 2 (4) 1 (1) 0 3 (1)
ANRNI 1 (2) 3 (2) 1 (1) 5 (2)
AIC/RS/NI 1 (2) 0 0 1 (0.4)
AIC/RT/NI 1 (2) 0 0 1 (0.4)
AICNI 1 (2) 1 (1) 0 2 (1)
AIRNI 6 (11) 41 (31) 25 (30) 72 (27)
AIRNI/L 0 0 1 (1) 1 (0.4)
AIRT/NI 1 (2) 0 4 (5) 5 (2)
AIRT/NI/L 0 1 (1) 2 (2) 3 (1)
AIRTI 2 (4) 0 1 (1) 3 (1)
Total 53 (100) 133 (100) 83 (100) 269 (100)
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Nine additional isolates (8.8%) had two copies of the 
gene. All isolates with multiple copies of Pfmdr1 were 
collected in Kobeni. All other isolates (n = 92) carried a 
single copy of Pfmdr1 gene. The copy number variations 
of Pfmdr1 were not associated with any mutation of this 
gene or with Pfcrt SNP (P > 0.05).
Discussion
The present study was conducted during the peak sea-
son of malaria transmission in three districts in the Hodh 
Elgharbi region. A high prevalence of mutant K76T Pfcrt 
allele was observed in the present study. This finding is 
in agreement with the previous clinical and molecular 
studies, confirming that Pfcrt is useful for the detection 
and surveillance of chloroquine-resistant P. falciparum in 
Hodh Elgharbi region [13].
The present study also revealed the high prevalence of 
Y184F and, to a lower extent, N86Y mutations in Pfmdr1 
gene. It has been suggested that Pfmdr1 mutations may 
play a role in modulating the levels of resistance to sev-
eral drugs [23]. Amodiaquine treatment failure has been 
associated with the selection of P. falciparum isolates car-
rying the mutant Pfcrt 76T allele and Pfmdr1 haplotype 
86Y, Y184, and 1246Y [23–26]. In the present study, the 
majority of isolates (68.9% with either pure mutant or 
mixed alleles) had the mutant Pfcrt 76T allele, but the 
Pfmdr1 mutant haplotype associated with amodiaquine 
resistance was rare (for 1246Y mutant, two of 190 iso-
lates, 1.0%). These molecular findings are in agreement 
with the high clinical efficacy of artesunate-amodiaquine 
in Kobeni (98.2% efficacy on day 28 after PCR correc-
tion) and the fact that amodiaquine monotherapy had 
not been used before adoption of ACT in the country 
[2]. An opposite trend for the selection of P. falciparum 
isolates with Pfmdr1 haplotype N86, 184F, and D1246 
has also been reported after artemether-lumefantrine 
treatment [8–10, 26]. Since artesunate-amodiaquine and 
artemether-lumefantrine are widely employed to treat P. 
falciparum in Mauritania, further surveillance of ACT 
resistance can be pursued using the combination of Pfcrt, 
Pfmdr1 and kelch 13 as surrogate markers for resistance 
to these drugs, in parallel with regular clinical evaluation 
of ACT efficacy. The limitations of the study on Pfmdr1 
include the lack of complete molecular data for all iso-
lates due to sub-optimal PCR conditions for the fragment 
spanning codons 1034, 1042, and 1246, the limited quan-
tity of DNA available, and possible degradation of DNA 
due to poor storage conditions. The present study was 
conducted before the discovery of kelch 13, and insuf-
ficient blood sample did not allow further study on this 
novel marker.
Pfmdr1 gene copy number is pertinent for monitor-
ing possible emergence of resistance to amino alcohols 
(lumefantrine and mefloquine), which is also influenced 
by Pfcrt and Pfmdr1 alleles [8–10]. At present, the pro-
portion of isolates with increased gene copy number is 
limited in Mauritania, but further monitoring is required, 
in particular in Kobeni, where isolates with multiple cop-
ies of Pfmdr1 gene were found. In addition, an evaluation 
of the efficacy of artemether-lumefantrine in Kobeni is 
necessary to establish baseline clinical data.
Pfdhps A437G substitution is one of the components of 
the ‘quintuple Pfdhps-Pfdhfr mutations’ associated with 
SP resistance [27]. The analysis of molecular markers in 
the present study revealed the presence of 437G in 23% 
(35% including mixed alleles) of the isolates: 19% (38% 
including mixed alleles) in Aioun and 14% (24% including 
mixed alleles) in Kobeni. In an earlier study conducted in 
1998, there were 22 and 16% of mutant 437G in Aioun 
and Kobeni, respectively [14]. There was only a slight 
increase in the proportion of mutant Pfdhps 437G allele 
in Kobeni after 12  years. By contrast, the proportion of 
mutant 437G allele almost doubled during the same 
period in Aioun. However, the other Pfdhps component 
of the ‘quintuple mutant’, K540E, was observed in only 
four of 264 (1.5%) isolates in the present study and none 
in the 1998 study [14].
Triple Pfdhfr mutant (AIRNI) was present in a total of 
106 of 269 (39%) isolates, either as pure alleles (n = 72, 
27%) or mixed alleles (n = 34, 12.6%). In an earlier study, 
Eberl et al. reported 16.9% (ten of 59 isolates) and 12.6% 
(13 of 103 isolates) of triple Pfdhfr mutants in Aioun and 
Kobeni, respectively [14]. The proportions of triple Pfd-
hfr mutants increased two- to three-fold in Aioun and 
Kobeni between 1998 and 2010. This observation is con-
sistent with the frequent use of SP for the treatment of 
uncomplicated malaria until 2006 and the continuous 
use of this drug for intermittent preventive treatment 
in pregnant women since 2006 [28]. The progression of 
Pfdhps mutants overtaking wild-type isolates between 
1998 and 2010 seems to be slow in Kobeni compared to 
Tintane and Aioun where mutations in both Pfdhps and 
Pfdhfr occurred at a similar rate between 1998 and 2010. 
Quintuple mutant occurred rarely in the present study. 
Moreover, Pfdhfr I164L substitution, which confers a 
Table 6 Pfmdr1 gene copy number among  P. falciparum 





Aioun Kobeni Tintane Total
One 6 (100) 78 (88.6) 8 (100) 92 (90.2)
Two 0 9 (10.3) 0 9 (8.8)
Three 0 1 (1.1) 0 1 (1.0)
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high level of pyrimethamine resistance, was found as 
mixed alleles in few isolates. The results of the molecular 
assays suggest that SP is still useful in targeted popula-
tion (i.e., in pregnant women and possibly in infants) for 
intermittent preventive treatment. Other studies have 
suggested that intermittent preventive treatment with SP 
remains effective for fetal and maternal protection even 
in areas of high resistance to SP [29].
Current knowledge on malaria epidemiology is still 
inadequate to develop a concerted plan to control cross-
border malaria in the study area. In addition to clinical 
and molecular studies on drug-resistant malaria and 
entomological surveys, sociological studies are needed to 
understand the patterns of human population movement 
of the nomads, refugees and local travellers along and 
across the Malian–Mauritanian border. These difficul-
ties are compounded by the presence of P. vivax, which 
is notoriously difficult to eliminate due to hypnozoites, 
requiring primaquine for radical cure. One recent study 
failed to detect P. vivax along the Malian–Mauritanian 
border (Selibaby, Ould Yenge, Aioun, Kobeni, Timbedra, 
Nema) [30]. However, the results of other studies, includ-
ing the present study, indicate the presence of P. vivax in 
this hotspot [15, 16, 31]. A coordinated regional malaria 
control programme will be required in the effort to con-
trol cross-border malaria that involves both P. falciparum 
and P. vivax [32].
Conclusions
Despite the introduction and use of ACT in Mauritania 
since 2006, the prevalence of genetic polymorphisms 
associated with drug resistance reached levels of con-
cern. Although the prevalence of quintuple Pfdhfr-
Pfdhps mutants was low in the present study, the high 
percentage of triple Pfdhfr mutants associated with the 
key Pfdhps A437G mutation, the high prevalence of 
mutant Pfcrt allele, and, to a lesser extent, the observed 
mutations in Pfmdr1 gene may jeopardize the future of 
seasonal malaria chemoprevention based on amodi-
aquine-SP and the use of SP for intermittent preventive 
treatment in pregnancy. Further molecular studies using 
these molecular markers, in parallel with clinical evalua-
tion of currently deployed anti-malarial drugs, are war-
ranted to monitor and anticipate the possible spread of 
drug-resistant P. falciparum in the malaria hotspot along 
the Malian–Mauritanian border. A new marker, kelch 13, 
should be added in future molecular surveillance activi-
ties for a more complete data collection.
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